

P2192 Molecular detection of *Aspergillus* and corresponding azole resistance markers: systematic comparison of two commercial PCR test kits, AsperGenius and MycoGENIE

Daniel Goldenberger¹, Nina Khanna², Elisabeth Wehrle^{3,2}, Helena Seth-Smith^{4,1}, Doris Hohler¹, Vladimira Hinic¹, Adrian Egli^{4,1}

¹ Clinical Microbiology, University Hospital Basel, Basel, Switzerland, ² Department of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, ³ Department of Infectious Diseases & Hospital Epidemiology, Hospital Delémont, ⁴ Applied Microbiology Research, Department of Biomedicine, University of Basel

Background:

Azole resistance in *Aspergillus fumigatus* has emerged as a global health problem. Conventional methods such as culture have a reduced sensitivity and phenotypic susceptibility testing is laborious and time-consuming. Novel molecular diagnostic tools have the potential to provide more reliable results within hours.

Materials/methods:

We compared two commercially available diagnostic test kits for detection of *A. fumigatus* / species DNA as well as identification of distinct molecular azole resistance markers: the AsperGenius[®] (AG) and MycoGENIE[®] (MG) tests. The assays were evaluated with six azole-susceptible and seven azole-resistant *A. fumigatus* reference isolates which were also analyzed using whole genome sequencing. Twelve *Aspergillus non-fumigatus* strains were used to test specificity. In addition, 46 clinical samples (31 BALs, 13 biopsies, 2 miscellaneous) from 41 patients tested positive by an in-house ITS region-based *Aspergillus* PCR were investigated.

Results:

Analysis of all *Aspergillus* culture isolates showed expected findings in both tests. The analytical sensitivity for *A. fumigatus* was from 1.5 to 15 fg in both tests, corresponding to 0.05 to 0.5 organisms per reaction. However, detection of azole resistance resulted in a reduced sensitivity of factor 10 to 100. The detection of *Aspergillus* organisms in clinical samples is shown in the table. In 18/37 *A. fumigatus* positive samples (48.6%), azole testing was successful by the AG test from which 14 showed wildtype (sensitive) markers and 4 TR34/L98H mutations. These four samples originated from a patient with simultaneous isolation of TR34/L98H-harbouring *A. fumigatus*. MG could not differentiate between a sensitive or a negative result and in contrast to AG 4/4 TR34/L98H-positive clinical samples could not be identified.

Conclusions:

In accordance with previous studies, the MG test shows a slightly higher sensitivity for detection of *A. fumigatus* DNA in comparison to the AG assay. However, azole susceptibility results from clinical samples reveals a reduced reliability in the MG assay.

| Table: <i>Aspergillus</i> spp.-positive clinical samples (n=46) | | | |
|--|--------------------|-------------------------|-----|
| MG assay | AG assay | Clinical samples | |
| <i>A.fumigatus</i> | <i>A.fumigatus</i> | <i>Aspergillus</i> spp. | No. |
| + | + | + | 37 |
| + | - | - | 4 |
| - | - | + | 3 |
| - | - | - | 2 |
| Total | 46 | | |

29TH ECCMID
13-16 APRIL 2019 AMSTERDAM, NETHERLANDS
POWERED BY M-ANAGE.COM

